Mitomycin C and Radiotherapy for Tumor Control
Author Information
Author(s): Budach W, Paulsen F, Welz S, Classen J, Scheithauer H, Marini P, Belka C, Bamberg M
Primary Institution: Department of Radiation Oncology, University of Tuebingen
Hypothesis
Does Mitomycin C inhibit tumor cell repopulation when combined with radiotherapy?
Conclusion
Mitomycin C significantly reduces the risk of local recurrence and inhibits tumor cell repopulation when used with fractionated radiotherapy.
Supporting Evidence
- Mitomycin C alone resulted in a median time to local tumor progression of 23 days.
- Fractionated irradiation alone resulted in a median time to local tumor progression of 31 days.
- Combined Mitomycin C and fractionated irradiation resulted in a median time to local tumor progression of 65 days.
- Mitomycin C decreased the relative risk of local recurrence by 94%.
- Repopulation accounted for 1.33 Gy per day after fractionated irradiation alone and for 0.68 Gy per day after combined treatment.
Takeaway
This study shows that a medicine called Mitomycin C can help stop cancer cells from growing back when used with radiation treatment.
Methodology
The study used NMRI (nu/nu) mice with a human squamous cell carcinoma to test the effects of Mitomycin C and radiotherapy on tumor progression.
Potential Biases
The investigators were not blinded to the treatment groups during measurements.
Limitations
Only one tumor cell line was studied, and the effects may not be generalizable to other tumors or drugs.
Participant Demographics
Immunodeficient NMRI-(nu/nu)-nude mice aged 4–6 weeks were used.
Statistical Information
P-Value
P=0.02
Confidence Interval
95% confidence limits: 17–43 days for MMC, 25–35 days for radiotherapy, 58–73 days for combined treatment
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website